



## **Certification of Substances Department**

## Certificate of suitability No. R0-CEP 2011-004-Rev 02

- 1 Name of the substance:
- 2 TAMSULOSIN HYDROCHLORIDE
- 3 Name of holder:
- 4 SCINOPHARM TAIWAN, LTD.
- 5 No. 1, Nan-Ke 8th Road
- 6 Taiwan-74144 Shan-Hua, Tainan
- 7 Site(s) of production:
- 8 SEE ANNEX 1

9	_	THIS CERTIFICATE SUPERSEDES THE DREVIOUS CERTIFICATE	_	
10		<u>Notice</u>	]	
11	Aft	NOT FOR REGISTRATION PURPOSES		
11 12	pro	For filing purposes please contact ScinoPharm Taiwan	subsequent	
13	cer	to obtain a complete "controlled copy" of this CEP.	i annex, we	
14	mor	The state of the s	sion of the macopoeia,	
15	cur	ScinoPharm Taiwan- Regulatory Technical Services	ned below,	
16	bas	(SPT.RTS@scinopharm.com.tw)	med Below,	
17	In	the last steps of the synthesis ethanol is used as solvent. Its residual content	is limited by	
18	th	e test for loss on drying described in the monograph with a limit of not more than	0.5%.	
19	Test for residual catalysts by ICP-MS		(Annex 2)	
20	Pa	alladium not more than 10 ppm	,	
21	Ni	ckel not more than 20 ppm		
22	The re-test period of the substance is 5 years if stored in double polyethylene bags placed in a			
23		olyethylene drum.		
24	The holder of the certificate has declared the absence of use of material of human or animal			
25	origin in the manufacture of the substance.			
26	The submitted dossier must be updated after any significant change that may alter the quality,			
27	safet	y or efficacy of the substance.		
28	Manu	Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice		
29	and i	n accordance with the dossier submitted.		

- 30 Failure to comply with these provisions will render this certificate void.
- 31 This certificate is granted within the framework of the procedure established by the European
- 32 Pharmacopoeia Commission [Resolution AP-CSP (07) 1] for a period of five years starting from
- 33 27 June 2013. Moreover, it is granted according to the provisions of Directive 2001/83/EC and
- 34 Directive 2001/82/EC and any subsequent amendment, and the related guidelines.
- This certificate has two annexes, the first of 1 page and the second of 3 pages.
- 36 This certificate has:
- 37 lines.

On behalf of the Director of EDOM



Strasbourg, 23 February 2017

DECLARATION OF ACCESS (to be filled in by the certificate holder under their own responsibility)

SCINOPHARM TAIWAN, LTD., as holder of the certificate of suitability

## Notice NOT FOR REGISTRATION PURPOSES

here

For filing purposes please contact ScinoPharm Taiwan to obtain a complete "controlled copy" of this CEP.

to u Mar

ScinoPharm Taiwan- Regulatory Technical Services (SPT.RTS@scinopharm.com.tw)

wing

The holder also certifies that no significant changes to the operations as described in the CEP dossier have been made since the granting of this version of the certificate.

Date and Signature (of the CEP holder):

Address: 7 Allée Kastner, CS 30026 F-67081 Strasbourg (France) Tel: +33 (0) 3 88 41 30 30 – Fax: +33 (0) 3 88 41 27 71 - e-mail: cep@edqm.eu Internet: http://www.edqm.eu